跳到正文
原文
NEJM· @NEJM · X·· 50 分钟前精选AI 评分75
AI 导读

NEJM报道,一项纳入成人IgA肾病患者的III期随机试验I CAN中期分析显示,终末补体抑制剂ravulizumab较安慰剂显著降低蛋白尿。完整结果与研究摘要见 https://nej.md/4iwTFdS。

推荐理由

III期I CAN试验的中期分析显示ravulizumab在IgA肾病患者中降蛋白尿优于安慰剂,可供关注补体通路治疗的人参考。

正文

An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo. Full I CAN trial results and Research Summary: https://nej.md/4iwTFdS

来源:NEJM · x.com